Efficacy and safety of the Rezum system for the treatment of catheter‐dependent urinary retention: Three‐year real‐world outcomes in a multimorbid, multiethnic population
LUTS: Lower Urinary Tract Symptoms · 2023
DOI: 10.1111/luts.12482 ↗Kurz gefasst
Klinische Studie in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, 2023. Verfasst von Mustufa Babar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Lower Urinary Tract Symptoms, Prostatic Hyperplasia, Urinary Retention, Urinary Tract Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate the long‐term real‐world efficacy and safety of Rezum for the treatment of catheter‐dependent urinary retention in a multimorbid, multiethnic population.
Methods
A single‐office, retrospective study was conducted on patients treated with Rezum between 2017 and 2019. Patients were included if they had catheter‐dependent urinary retention prior to treatment and at least one follow‐up within 36 months postoperatively. Patient demographics, procedural characteristics, adverse events (AEs), and outcome measures, including benign prostate hyperplasia (BPH) medication usage and postvoid residual (PVR), were collected at 3, 6, 12, and/or 36 months postoperatively. Regret was assessed at 36 months using the 5‐item Decisional Regret Scale (DRS).
Results
A total of 27 patients met the inclusion criteria, with the majority being Asian (29.6%), followed by non‐Hispanic Black (26.0%) and Hispanic (22.2%). Most patients (77.8%) had at least one comorbidity. Trial of void (TOV) was attempted at a median of 8 days (7, 13). Fourteen patients (51.9%) failed their initial TOV. Median time until catheter independence was 13.5 days (8.5, 28.8). Common AEs included urinary retention (51.9%), urinary tract infections (UTIs) (25.9%), and dysuria (25.9%). All cases of UTIs (7/7) and most cases of dysuria (6/7) occurred in patients who failed their initial TOV. At 36 months, there was a significant median percentage change in PVR (−100.0% [−100.0, −36.7], p = .049), and 40.4% of patients discontinued their BPH medications ( p = .001). Of the 11 patients who filled out the DRS, 10 (90.9%) agreed/strongly agreed that they made the right decision. By 36 months, 4 patients (14.8%) underwent reoperation and 24 (88.9%) remained catheter‐independent.
Conclusions
At long‐term follow‐up, Rezum effectively treated catheter‐dependent urinary retention with minimal decisional regret. In patients with urinary retention, urologists should consider delaying TOV until 2 weeks postoperatively to maximize the likelihood of a successful TOV and minimize the risk of AEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Albert Einstein College of Medicine, Bronx, New York, USA.
- DSS Urology, Queens Village, New York, USA.
- Department of Urology, Montefiore Medical Center, Bronx, New York, USA.
ORCID-Profile: Mustufa Babar, Kevin Labagnara, Kevin Tang
Zitieren
APA
Babar, M., Masoud, Z., Labagnara, K., Loloi, J., Sayed, R., Singh, S., Tang, K., Syed, U., & Ciatto, M. (2023). Efficacy and safety of the Rezum system for the treatment of catheter‐dependent urinary retention: Three‐year real‐world outcomes in a multimorbid, multiethnic population. LUTS: Lower Urinary Tract Symptoms. https://doi.org/10.1111/luts.12482
Vancouver
Babar M, Masoud Z, Labagnara K, Loloi J, Sayed R, Singh S, et al. Efficacy and safety of the Rezum system for the treatment of catheter‐dependent urinary retention: Three‐year real‐world outcomes in a multimorbid, multiethnic population. LUTS: Lower Urinary Tract Symptoms. 2023. doi:10.1111/luts.12482
BibTeX
@article{Babar2023,
author = {Babar, Mustufa and Masoud, Zaki and Labagnara, Kevin and Loloi, Justin and Sayed, Rahman and Singh, Sandeep and Tang, Kevin and Syed, Umar and Ciatto, Michael},
title = {Efficacy and safety of the Rezum system for the treatment of catheter‐dependent urinary retention: Three‐year real‐world outcomes in a multimorbid, multiethnic population},
journal = {LUTS: Lower Urinary Tract Symptoms},
year = {2023},
doi = {10.1111/luts.12482}
}
EUVIMED